Replies to post #116232 on Anavex Life Sciences Corp (AVXL)

[blue finch]

Thanks 66a
Great reading you

[OFP]

I can find no authoritative source that claims the three existing Alzheimer’s drugs, Razadyne® (galantamine), Exelon® (rivastigmine), and Aricept® (donepezil) work by restoration of neuron homeostasis resulting from their putative sigma-1 receptor agonism

look harder

I can see no evidence that any of these existing drugs will out-compete Anavex 2-73

The onus is on AVXL to provide evidence they can ever catch up to existing drugs not the reverse.

Side note: "I can see no evidence that..." is an extraordinarily weak statement. For example, I can see no evidence that I won't win tonight's Powerball.

[frrol]

Donepezil is an S1 agonist with a higher binding affinity than 2-73 and apparently stronger effects according to some biomarkers as proposed in a recent paper (cited by our company itself). Setting no evidence by lack of DD is not a substitute for no evidence itself, let alone no affirmative evidence. Such a difference is crucial in science research, don't you think.

What would be great is an explanation of this. I'm not expecting this from you, but from the company. Of course, if our human trials show robust efficacy, it is less important. Efficacy is primary for the FDA.